hit counter
Athenex, Inc. (ATNX) Stock News Sentiment & Price - Sentifly
ATNX - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Athenex, Inc. (ATNX)

USA
Biotechnology
NASDAQ
ATNX Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ATNX Latest news
GlobeNewsWire
Neutral
Athenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mutated p53, KRAS, and EGFR for the Development of Autologous and Allogeneic Cell Therapies
2021-11-09 08:00

Athenex plans to expand the allogeneic NKT cell R&D pipeline with these new licensed TCRs to target solid tumors Athenex plans to expand the allogeneic NKT cell R&D pipeline with these new licensed TCRs to target solid tumors

Seeking Alpha
Neutral
Athenex, Inc. (ATNX) CEO Johnson Lau on Q3 2021 Results - Earnings Call Transcript
2021-11-07 00:59

Athenex, Inc. (ATNX) CEO Johnson Lau on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Positive
Athenex (ATNX) Reports Q3 Loss, Tops Revenue Estimates
2021-11-04 12:13

Athenex (ATNX) delivered earnings and revenue surprises of 19.51% and 66.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
Athenex Presents Interim Data from ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at 63rd ASH Annual Meeting and Exposition
2021-11-04 09:15

Results from five patients showed best responses of 2 partial responses (PR), 1 complete response with incomplete hematological recovery (CRi) and 1 complete response (CR).

Zacks Investment Research
Negative
Athenex (ATNX) Sees Hammer Chart Pattern: Time to Buy?
2021-11-03 08:26

Athenex (ATNX) has been struggling lately, but the selling pressure may be coming to an end soon.

GlobeNewsWire
Neutral
Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021
2021-10-22 16:05

BUFFALO, N.Y., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2021, on Thursday, November 4, 2021. Athenex's management team will host a conference call and live audio webcast at 10:00 a.m. Eastern Time.

GlobeNewsWire
Neutral
Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 5, 2021
2021-10-21 08:00

BUFFALO, N.Y., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2021, on Friday, November 5, 2021, before the market opens. Athenex's management team will host a conference call and live audio webcast at 8:00am Eastern Time.

GlobeNewsWire
Neutral
Athenex and the Center for Cell and Gene Therapy Announce Allowance of Our First U.S. Patent Claims Around CAR-NKT Cell Therapy
2021-10-18 08:15

Patent includes a pharmaceutical composition claim comprising a plurality of genetically modified CD62L-positive human NKT cells comprising at least one chimeric antigen receptor (CAR)

Zacks Investment Research
Negative
After Plunging 25.6% in 4 Weeks, Here's Why the Trend Might Reverse for Athenex (ATNX)
2021-10-12 13:23

Athenex (ATNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

GlobeNewsWire
Neutral
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic Breast Cancer
2021-10-11 08:00

BUFFALO, N.Y., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it recently held a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for oral paclitaxel and encequidar (Oral Paclitaxel) in metastatic breast cancer (mBC). The purpose of the meeting was to review with the FDA a proposed design for a new clinical trial intended to address the deficiencies raised in the Complete Response Letter received in February 2021 and discuss the potential regulatory path forward for Oral Paclitaxel in mBC in the U.S.

Loading more news...